アブストラクト
| Title | VOL. (30) がん悪液質症状改善薬としての六君子湯の可能性 |
|---|---|
| Subtitle | がんサポーティブケアのいま・これから |
| Authors | 上園保仁, 野中美希 |
| Authors (kana) | |
| Organization | 東京慈恵会医科大学 疼痛制御研究講座 |
| Journal | 新薬と臨牀 |
| Volume | 70 |
| Number | 1 |
| Page | 56-62 |
| Year/Month | 2021 / 1 |
| Article | 報告 |
| Publisher | 医薬情報研究所 |
| Abstract | 「はじめに」進行がん患者の8割近くは倦怠感, 食思不振, 体重減少といった「悪液質」と呼ばれる症状を呈し, 生活の質(Quality of Life:QOL)を著しく低下させる. 多くのがん種にがん悪液質の報告があるが, 特に膵臓がん, 胆管がん, 胃がん患者は高頻度でがん悪液質症状を呈する. これまでのがん悪液質研究のなかで, がん悪液質の予防ならびに症状の改善は患者のQOLを向上させることが示されている. がん悪液質の成因, 素因には, がん細胞自身が出す因子によるもの, がん細胞からの因子に反応して起こる宿主の免疫および代謝異常などの一次性反応によるものなどが報告されているものの, その本態は不明である. 「がん悪液質の定義および診断基準」European Palliative Care Research Collaborative(EPCRC)という欧州の緩和ケア研究組織によると, がん悪液質は「通常の栄養サポートでは完全に回復することができず, 進行性の機能障害に至る, 骨格筋量の持続的な減少(脂肪量減少の有無にかかわらず)を特徴とする多因子性の症候群」と定義される. |
| Practice | 臨床医学：一般 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) Tisdale MJ. Biology of cachexia. J Natl Cancer Inst. 1997, 89:1763-1773.
- 2) 日本がんサポーティブケア学会, 内藤立暁, 高山浩一, 田村和夫(監修). がん悪液質ハンドブック-「がん悪液質:機序と治療の進歩」を臨床に役立てるために. 東京, 日本がんサポーティブケア学会:2019. p.6.
- 3) Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia:an international consensus. Lancet Oncol. 2011;12:489-495.
- 4) Madeddu C, Maccio A, Mantovani G. Multitargeted treatment of cancer cachexia. Crit Rev Oncog. 2012;17:305-314.
- 5) Marceca GP, Londhe P, Calore F. Management of cancer cachexia:Attempting to develop new pharmacological agents for new effective therapeutic options. Front Oncol. 2020;10:298.
残りの21件を表示する
- 6) Bar-Sela G, Zalman D, Semenysty V, Ballan E, The effects of dosage-controlled cannabis capsules on cancer-related cachexia and anorexia syndrome in advanced cancer patients:pilot study. Integr Cancer Ther. 2019;18:1534735419881498.
- 7) Turcott JG, Del Rocio Guillen Nunez M, Flores-Estrada D, et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients:a randomized, double-blind clinical trial. Support Care Cancer. 2018;26:3029-3038.
- 8) Jatoi A, Ritter HL, Dueck A, et al. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients(NO1C9). Lung Cancer. 2010;68:234-239.
- 9) Rigas JR, Schuster M, Orlov SV, et al. Effect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer(NSCLC):results of a phase II randomized, double-blind safety and efficacy trial. J Clin Oncol. 2010;28:7622.
- 10) Hickish T, Andre T, Wyrwicz L, et al. MABp1 as a novel antibody treatment for advanced colorectal cancer:a randomized, double-blind, placebo-controlled, phase 3 study. Lancet Oncol, 2017;18:192-201.
- 11) Lai V, George J, Richey L, et al. Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract. Head Neck. 2008;30:67-74.
- 12) Mantovani G, Maccio A, Madeddu C, et al. Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J Mol Med. 2010;88:85-92.
- 13) Gordon JN, Trebble TM, Ellis RD, et al. Thalidomide in the treatment of cancer cachexia:a randomized placebo controlled trial. Gut, 2005;54:540-545.
- 14) Mantovani G. Randomized phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia. Eur Rev Med Pharmacol Sci. 2010;14:292-301.
- 15) Yennurajalingam S, Willey JS, Palmer JL, et al. The role of thalidomide and placebo for the treatment of cancer-related anorexiacachexia symptoms:results of a double-blind placebo-controlled randomized study. J Palliat Med. 2012;15:1059-1064.
- 16) Padhi D, Higano CS, Shore ND, et al. Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2014;99:E1967-1975.
- 17) Uezono Y, Miyano K, Sudo Y, et al. A review of traditional Japanese medicines and their potential mechanism of action, Curr Pharm Des. 2012;18:4839-4853.
- 18) Argiles JM, Stemmler B. The potential of ghrelin in the treatment of cancer cachexia. Expert Opin Biol Ther. 2013;13:67-76.
- 19) Chopin LK, Seim I, Walpole CM, et al. The ghrelin axis-does it have an appetite for cancer progression?. Endocr Rev. 2012;33:849-891.
- 20) DeBoer MD. The use of ghrelin and ghrelin receptor agonists as a treatment for animal models of disease:efficacy and mechanism. Curr Pharm Des. 2012;18:4779-4799.
- 21) Takeda H, Sadakane C, Hattori T, et al. Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT2 receptor antagonism. Gastroenterology. 2008;134:2004-2013.
- 22) Yakabi K, Sadakane C, Noguchi M, et al. Reduced ghrelin secretion in the hypothalamus of rats due to cisplatin-induced anorexia. Endocrinology. 2010;151:3773-3782.
- 23) Matsumura T, Arai M, Yonemitsu Y, et al. The traditional Japanese medicine Rikkunshito increases the plasma level of ghrelin in humans and mice. J Gastroenterol. 2010;45:300-307.
- 24) Fujitsuka N, Asakawa A, Uezono Y, et al. Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival. Transl Psychiatry. 2011;1:e23.
- 25) Sadakane C, Muto S, Nakagawa K, et al. 10-Gingerol, a component of rikkunshito, improves cisplatin-induced anorexia by inhibiting acylated ghrelin degradation. Biochem Biophys Res Commun. 2011;412:506-511.
- 26) 日本漢方生薬製剤協会. 漢方の将来ビジョン研究会. https://www.nikkankyo.org/action/action4.htm
